Connect with us

Technology

LIGHT AI ACHIEVES ISO 13485 AND MDSAP CERTIFICATION, ADVANCING REGULATORY READINESS FOR HEALTH CANADA SUBMISSION OF QUICKSCAN™ SOFTWARE PLATFORM

Published

on

Quality Management System Certification Marks Key Regulatory Milestone for Light AI’s Software as a Medical Device Platform

VANCOUVER, BC, June 29, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF) an artificial intelligence health technology company developing Software as a Medical Device (“SaMD”) solutions, is pleased to announce that it has successfully completed its Quality Management System”” audit and has been certified as being in conformity with ISO 13485:2016 and the Medical Device Single Audit Program (“MDSAP”) by Intertek.

The MDSAP certification confirms that Light AI’s quality management system meets internationally recognized standards for the design, development, manufacture, and distribution of AI/ML powered devices used to screen, monitor, and assist in the detection of ENT infections management of medical devices and Software as a Medical Device technologies for Canada, the United States and Australia.

Achievement of MDSAP and ISO 13485 certification represents a significant regulatory milestone for the Company and supports its planned regulatory submissions for its QuickScan™ and QuickScan™ Strep A software platforms in Canada.

The certification covers the Company’s quality management processes associated with the development of QuickScan™ software-based medical technologies and establishes the operational framework required to support ongoing regulatory, clinical, and commercialization activities.

“As we continue executing our regulatory strategy, achieving MDSAP and ISO 13485 certification is an important accomplishment for Light AI,” said John R. Luna, Chief Executive Officer of Light AI. “This certification demonstrates our commitment to maintaining a robust medical device quality management system and reflects the significant work completed by our team to align our operations with internationally recognized medical device standards. With this milestone achieved, we are positioned to advance our planned Health Canada regulatory submissions for QuickScan™ Strep A.”

The Company’s QuickScan™ Strep A platform is being developed as Software as a Medical Device solutions intended to support healthcare professionals in the assessment of patients presenting with symptoms consistent with pharyngitis and potential Group A Streptococcus (“Strep A”) infection.

MDSAP allows recognized auditing organizations to conduct a single regulatory audit of a medical device manufacturer’s quality management system that satisfies the requirements of multiple participating regulatory jurisdictions including Canada, Australia and the United States. ISO 13485 is the internationally recognized quality management standard specific to the medical device industry and is widely utilized by regulators and manufacturers globally.

Light AI believes that completion of its MDSAP and ISO 13485 certification establishes an important foundation for future regulatory submissions, including the Company’s planned Health Canada Medical Device License application for QuickScan™ Strep A.

The Company will continue to advance its regulatory, clinical validation, and commercialization activities and expects to provide updates regarding Health Canada submission timing and other key milestones as appropriate.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI 
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to its anticipated regulatory submissions for the Company’s QuickScan™ and QuickScan™ Strep A software platforms in Canada; the Company’s business plan; and QuickScan™ Strep A platform being developed as Software as a Medical Device solutions and that it will support healthcare professionals in the assessment of patients. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.

Continue Reading

Technology

commercetools Named a Leader in 2026 Gartner® Magic Quadrant™ for Digital Commerce as AI Reshapes the Market

Published

on

By

commercetools is a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Commerce for the seventh consecutive year.commercetools has been driving AI innovation on how enterprises build, operate and sell, including capabilities like Sphere, Commerce MCP and commercetools for Builders.commercetools is helping global enterprises modernize complex commerce operations and prepare for a future where both people and AI agents discover, shop and transact.

BOSTON, Oct. 22, 2026 /PRNewswire/ — commercetools, the digital commerce AI company, today announced it has been positioned as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Commerce. This marks the seventh consecutive year commercetools has been recognized as a Leader in the report.

As AI reshapes commerce, commercetools is expanding how it supports the enterprises who build and operate commerce experiences, and the shoppers who use them. Global enterprises including JD Sports, Nederlandse Spoorwegen, Chemist Warehouse and Mirion Technologies are using commercetools to modernize complex digital commerce, accelerate growth and adopt new AI-powered ways of operating and selling.

“Commerce is moving from systems that simply respond to human instructions toward systems that can increasingly understand, decide and act,” said Doug McNary, Chief Executive Officer at commercetools. “We’re proud to be named a Leader for the seventh consecutive year. Enterprises shouldn’t have to choose between the flexibility they need today and the autonomy they’ll need tomorrow. Our focus is giving them the technology to support both.”

Over the past year, commercetools has introduced new products and capabilities designed to bring AI across the commerce lifecycle:

Sphere: Brings together commercetools’ AI-native infrastructure and agent governance through Commerce MCP into a unified platform for enterprises to build, operate and sell with AI.commercetools for Builders: Helps anyone build, extend and evolve enterprise commerce faster with AI.AgentSphere: Lets enterprises build and manage AI agents to run commerce operations and agentic shopping, with appropriate guardrails to do so safely and at scale.Modular commerce offerings: Gives enterprises the flexibility to start with the capabilities they need and expand over time, accelerating time to value without requiring a full commerce transformation upfront.Commerce Integration Layer: Centralizes integration logic behind customer-facing experiences. Storefronts, mobile apps and AI agents connect through a unified layer hosted and maintained by commercetools.Smart Data Modeler: Uses AI to accelerate product data modeling, helping teams build the right foundation faster and reduce time-to-launch.

commercetools’ customers include large enterprises across retail, manufacturing, life sciences, healthcare and telecommunications in markets around the world.

To learn more about commercetools’ position as a Leader, download your complimentary copy of the 2026 Gartner Magic Quadrant report today.

About the Gartner Magic Quadrant for Digital Commerce

Gartner, Magic Quadrant for Digital Commerce Platforms, Aditya Vasudevan, Penny Gillespie, Sandy Shen, Jason Daigler, Mike Lowndes, 19 October 2026

Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About commercetools

commercetools, the global digital commerce AI company, helps enterprises transform commerce for the AI era. Built API-native from the start and AI-first by design, our technology enables agentic shopping experiences, automates commerce operations and gives businesses the agility to modernize faster, innovate continuously and operate more intelligently.

More than 500 global brands, retailers and enterprise companies rely on commercetools to power their digital commerce. Together, they process more than $100 billion in annualized GMV, over 700 million orders and more than one billion customer records on our platform.

Media Contact: comms@commercetools.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/commercetools-named-a-leader-in-2026-gartner-magic-quadrant-for-digital-commerce-as-ai-reshapes-the-market-302916761.html

SOURCE commercetools

Continue Reading

Technology

Phylo’s Biomni Lab to expand the use of AI agents in scientific research at Bayer

Published

on

By

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 /PRNewswire/ — Phylo, Inc. announced today a partnership with Bayer to deploy Biomni Lab, Phylo’s agentic AI platform to accelerate scientific research and evaluation. 

Under the agreement, Phylo will provide Bayer with full access to its agentic platform that helps Bayer scientists bring together scientific literature, biomedical data, and analytical methods in one environment, reducing the manual effort required to assemble and assess evidence. The platform’s inspectable workflows preserve the context behind each result, allowing researchers to review the underlying sources, methods, and execution and apply their own scientific judgment. Bayer scientists will gain access to Biomni Lab for workflows focused on assembling literature and omics evidence for drug discovery.

“This partnership reflects our belief that AI should expand scientific curiosity, not just speed up routine work. Giving our scientists an AI partner that brings rigor to every step lets them explore more ideas, ask bolder questions, and find the insights that move drug discovery forward, ultimately accelerating the pace at which we can bring new medicines to patients,” said Sai Jasti, Senior Vice President, Head of Data Science & Artificial Intelligence, Bayer Pharmaceuticals R&D.

“For agentic AI to matter in research, it has to earn the trust of the scientists doing the work. Bayer’s selection of Biomni Lab is a strong endorsement of the scientific rigor and AI capabilities we’ve built into the platform,” said Kexin Huang, Ph.D., Co-Founder and CEO of Phylo. “Our vision is an AI-native operating system for biopharma, where every scientist can direct a team of AI agents to pursue complex research questions. With Bayer, we aim to show what becomes possible when AI capabilities meet deep scientific expertise: more hypotheses explored, more discoveries made, and new possibilities for medicine.”

About Phylo

Phylo’s mission is to bring the best agentic intelligence to every biomedical scientist. Its enterprise-grade AI platform, Biomni Lab, is the first Integrated Biology Environment—a unified workspace where scientists collaborate with AI agents across literature research, experimental design, biological data analysis, and scientific decision-making.

Biomni Lab is now used by leading global biopharma, including Bayer, Chugai Pharmaceutical and Ono Pharmaceutical. Phylo is based in South San Francisco, backed by Andreessen Horowitz (a16z) and Menlo Ventures.

For more information, visit phylo.bio. To learn more about Biomni Lab, visit biomni.phylo.bio.

View original content to download multimedia:https://www.prnewswire.com/news-releases/phylos-biomni-lab-to-expand-the-use-of-ai-agents-in-scientific-research-at-bayer-302917080.html

SOURCE Phylo, Inc.

Continue Reading

Technology

Sandler Partners Welcomes Bryan Rias as Director, Sales Engineer, West Region

Published

on

By

New Hire Announcement | Independent Technology Distributor Sandler Partners grows its Sales Engineering team, adding Bryan Rias as Director, Sales Engineer, West Region.

REDONDO BEACH, Calif., Oct. 22, 2026 /PRNewswire/ — Sandler Partners, the leading independent Technology Solutions Distributor, announces the addition of Bryan Rias as Director, Sales Engineer, West Region, further strengthening its dedicated sales engineering team and the technical support available to Partners in the West Region.

Bryan brings more than two decades of experience designing and delivering complex technology solutions, including enterprise and Cloud architecture roles at Lumen/Savvis and IBM focused on infrastructure modernization and customer success. His expertise spans automation, edge computing, disaster recovery, application performance monitoring (APM), and DevSecOps. In his role, Bryan will support Partners across the West Region, aligning early with them on strategy and leading thoughtful discovery to help them find the right fit for each client.

For Bryan, strong relationships and solid values guide his life and form the foundation of his professional success, a perspective that fits naturally within the Sandler Partners community. When he is not working, Bryan spends time with his family, including his wife, three sons, and a grandson, RVing, boating, and biking, along with pursuing his passion for freediving.

“Bryan brings the kind of hands-on experience our Partners value: he’s been in the room on complex deals and knows how to turn a customer’s needs into the right solution,” says Justin Marano, Chief Revenue Officer, Sandler Partners. “He came to Sandler for the freedom to work across best-of-breed Providers, and our Partners in the West will feel that right away. He’s collaborative, grounded, and focused on helping Partners win. I’m excited to have him on the team.”

“I’m excited to get to work alongside our Partners, helping them navigate complex opportunities and bring clarity to technical decisions,” says Bryan. “For me, it all comes back to relationships. When you build them on trust and shared values, the results follow for our Partners and their clients. That’s something that the Sandler community really embodies, and I look forward to getting to work with our Partners!”

About Sandler Partners
Sandler Partners helps empower its network of leading independent Sales Partners to deliver a comprehensive range of technology solutions to organizations worldwide, including Cybersecurity, Artificial Intelligence (AI), Connectivity, Cloud, Colocation, Mobility, Internet of Things (IoT), and Continuity. Its community-focused approach enables Partners to identify the right solutions for customers quickly and objectively from a diverse portfolio of 220+ Providers. Partner sales agents, VARs, and MSPs gain access to an innovative suite of sales tools within the Sandler Portal—including SCOUT, Solutions Finder, Scout for Solutions, and the Marketing Center—several of which are AI-powered, all backed by a robust support network, dedicated Sales Engineering expertise, and rich marketing resources. Together, these tools and resources empower Partners to focus on what they do best: delivering quality, value, performance, innovative solutions, unmatched expertise, and exceptional service to their clients. Members of the Sandler Partners community also benefit from the industry’s strongest negotiated agreements and a dedicated team committed to ensuring commissions are accurately identified, tracked, and paid. For more information, visit www.sandlerpartners.com.

Sandler Partners – Media Contact
Tina S. Dyksterhouse
tina@sandlerpartners.com
310-861-2295

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandler-partners-welcomes-bryan-rias-as-director-sales-engineer-west-region-302916413.html

SOURCE Sandler Partners

Continue Reading

Trending